BiotechTube
DSG

DSG

San Diego, United States· Est.
dsg-us.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DSG is a specialized eClinical technology company that provides an integrated software platform for managing clinical trials. Its core offering, eCaseLink, unifies electronic data capture (EDC), direct data capture (DDC), and key decentralized clinical trial (DCT) tools into a single system, aiming to reduce site burden and enhance participant-centricity. With over 30 years of legacy software experience and a track record in supporting drug approvals, DSG positions itself as a flexible and cost-effective alternative to larger providers. The company was acquired by Signant Health in 2023, integrating its capabilities into a broader evidence generation suite.

Drug Delivery

Technology Platform

eCaseLink: A unified eClinical software platform integrating EDC, Direct Data Capture (DDC), eCOA, eConsent, RTSM, TeleVisit, and participant tracking for hybrid and decentralized clinical trials.

Opportunities

The rapid adoption of decentralized and hybrid clinical trial models creates strong demand for integrated platforms like DSG's eCaseLink.
The company's cost-effective positioning and 'study rescue' capability offer opportunities to win business from sponsors dissatisfied with larger, more expensive vendors.
Integration with Signant Health provides a larger sales channel and resources for accelerated product development.

Risk Factors

Post-acquisition integration with Signant Health carries execution risk, potentially disrupting operations and innovation.
DSG faces intense competition from large, well-funded public eClinical companies and must continuously invest to maintain its technological edge.
The business is also exposed to regulatory and data security risks inherent in handling sensitive clinical trial data.

Competitive Landscape

DSG competes in the crowded eClinical software market against large public companies like Medidata (Dassault Systèmes), Veeva Vault CDMS, and Oracle Health, as well as other DCT-focused players. It differentiates itself by offering a truly unified platform for both traditional and decentralized trials, agile implementation, and a cost-effective pricing model. Its acquisition by Signant Health positions it against other consolidated eClinical suites.

More companies in Digital Health & Biotech SaaS →More companies in United States →